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Abstract
Background: Community-based screening may be one solution to increase testing and treatment of sexually
transmitted infections in sexually active teenagers, but there are few data on the practicalities and cost of running
such a service. We estimate the cost of running a ‘Test n Treat’ service providing rapid chlamydia (CT) and gonorrhoea
(NG) testing and same day on-site CT treatment in technical colleges.
Methods: Process data from a 2016/17 cluster randomised feasibility trial were used to estimate total costs and service
uptake. Pathway mapping was used to model different uptake scenarios. Participants, from six London colleges, provided
self-taken genitourinary samples in the nearest toilet. Included in the study were 509 sexually active students (mean 85/
college): median age 17.9 years, 49% male, 50% black ethnicity, with a baseline CT and NG prevalence of 6 and 0.5%,
respectively. All participants received information about CT and NG infections at recruitment. When the Test n Treat team
visited, participants were texted/emailed invitations to attend for confidential testing. Three colleges were randomly
allocated the intervention, to host (non-incentivised) Test n Treat one and four months after baseline. All six colleges
hosted follow-up Test n Treat seven months after baseline when students received a £10 incentive (to participate).
Results: The mean non-incentivised daily uptake per college was 5 students (range 1 to 17), which cost £237 (range
£1082 to £88) per student screened, and £4657 (range £21,281 to £1723) per CT infection detected, or £13,970 (range
£63,842 to £5169) per NG infection detected.
The mean incentivised daily uptake was 19 students which cost £91 per student screened, and £1408/CT infection or
£7042/NG infection detected.
If daily capacity for screening were achieved (49 students/day), costs including incentives would be £47 per person
screened and £925/CT infection or £2774/NG infection detected.
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Conclusions: Delivering non-incentivised Test n Treat in technical colleges is more expensive per person screened than
CT and NG screening in clinics. Targeting areas with high infection rates, combined with high, incentivised uptake could
make costs comparable.
Trial registration: ISRCTN58038795, Assigned August 2016, registered prospectively.
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Background
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae
(NG) are bacterial sexually transmitted infections (STI),
responsible for almost half of STI diagnoses in England
and 62% in people aged 15–24 years [1]. However, uptake
of testing in many countries is too low to reduce infection
rates, and there may be delays in obtaining treatment. As
both infections can be symptomless, they can go un-
detected leading to problems such as pelvic inflammatory
disease, epididymitis, infertility and adverse birth out-
comes [2, 3]. Although NG is less common than CT, it is
a potentially more serious STI over which there are con-
cerns about antibiotic resistance [4]. Therefore, in this
study, participants diagnosed with NG were referred to
specialist clinics for further management [5, 6].
Self-collected vaginal swabs (for females) and first void
urine samples (for males) are ideal sample types for CT
and NG testing. Combining this with portable point of
care (POC) rapid test platforms gives potential to test
for these infections in a variety of community settings,
allowing people to receive results on the same day as
testing. Using POC CT/NG tests in high prevalence set-
tings may help reduce the burden of disease by making
testing more convenient and providing results faster,
thereby reducing the time to treatment [7, 8]. However,
data on the costs of providing community-based services
are limited. Previous cost analyses have primarily fo-
cused on using POC CT/NG tests in clinical settings
and/or based on modelled data [9–11]. There is an ur-
gent need for real life data to explore the economics and
practicalities of screening and treatment of STIs in the
community.
We used field data from the ‘Test n Treat’ (TnT) feasi-
bility trial of screening for CT/NG in further education/
technical colleges [5, 6]. (Further education colleges offer
both academic and practical courses such as plumbing
and hairdressing and take many students from socio-
economically deprived backgrounds.) The feasibility trial
aimed to measure uptake and acceptability of on-site
rapid STI testing and treatment to students, and recruit-
ment and follow up rates. In the current economic ana-
lysis, we estimated the cost per person screened and the
cost per CT/NG infection detected for:
 Non-incentivised testing
 Incentivised testing
 Maximum possible uptake (using incentives)
Methods
Aims
To estimate the costs of running a ‘Test n Treat’ service
providing rapid CT and NG testing and same day on-
site CT treatment in technical colleges and to estimate
the cost per person screened and per CT/NG infection
detected for: non-incentivised/standard testing; incenti-
vised testing-when participants were given £10 to be
tested; and with maximum possible uptake (using
incentives).
Intervention
The TnT cluster randomised feasibility trial recruited
sexually active students attending six technical colleges
in South London. ‘Test n Treat’ refers to testing students
for CT and NG on site at their college, giving them a same
day result, and offering same day on-site treatment from a
health adviser for students with a positive CT test. (As
mentioned earlier, students with NG were referred to a
sexual health clinic for specialist management.)
The protocol and main results of the TnT trial are
available elsewhere [5, 6]. In summary, 509 sexually ac-
tive ethnically diverse students aged 16–24 years were
recruited from communal areas in six technical colleges
in South London in October 2016 (Fig. 1). Participants
completed questionnaires on sexual lifestyle and pro-
vided self-taken genitourinary samples. We provided
information about the risks of CT/NG and explained
that as these baseline samples would not be tested for
7 months all participants should seek STI testing at a
sexual health clinic or from their family doctor inde-
pendently of the trial.
Three of the colleges were randomly assigned to re-
ceive TnT visits one and four months after recruitment.
Students previously recruited at these sites were texted/
emailed invitations to come to a classroom for confiden-
tial testing and same day on-site treatment. As previ-
ously, they were asked to provide self-taken urine
samples (males) or vaginal swabs (females) in the nearest
toilet. (In women, vaginal swabs are more reliable than
urines for detection of CT.) Samples were tested imme-
diately in a “pop-up” laboratory at the college using the
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GeneXpert® CT/NG test (Cepheid, Sunnyvale, CA, USA)
yielding a result in 90min [12]. The GeneXpert4/4 s ma-
chine - a portable unit weighing 10 kg - contains four
modules which can be used asynchronously to test four
separate samples. Three machines were used at each TnT
visit allowing 12 samples to be tested simultaneously.
Negative results were texted to participants (in a median
time of 2.1 h after providing a sample). The research
team’s nurse health adviser telephoned participants with
positive results and met them in another private room in
college (same day whenever possible) for confidential
treatment for CT, partner notification and/or referral (for
NG management). Students with CT who did not attend
for treatment in college, and those with dual CT/NG in-
fection, were referred to a sexual health clinic for further
management.
In the three control colleges, students received text
messages 1 month and 4months after recruitment
thanking them for their participation. For the outcome
assessment exploring change in CT prevalence, the TnT
service was offered in all six colleges at seven months -
when students received a £10 incentive for providing a
follow up sample (and questionnaire). The incentive was
suggested by our PPI group and intended to maximise
follow up.
Calculating costs and consumables
There were two types of costs involved in providing the
TnT service: the fixed or “daily” costs, i.e. costs incurred
irrespective of the number of people screened; and the
per person costs, i.e. the variable costs dependent on the
number of people screened. The components of deliver-
ing TnT included the cost of two healthcare assistants
organising CT/NG screening, and a health advisor pro-
viding treatment where CT was diagnosed, plus the cost
of travel, all equipment and consumables (Add-
itional file 1: Supplementary Table 1). There was no
charge from the participating colleges for use of their
rooms. (This is usual practice for visiting services which
are provided free and may benefit students.) Costs re-
flect 2018 prices and are presented in British pounds.
Currency conversion rates are taken from 1st June 2018,
and inflation rates are taken from mid-year [13, 14].
Uptake scenarios used to calculate screening costs
Variation in testing uptake impacts the per-person cost
of providing the service. As such, three different scenar-
ios are reported based on uptake:
1. The average (a), minimum (b), maximum (c), half
the average (d) and double the average (e), number
of students who used the non-incentivised service.
2. The average number of students who used the
incentivised service (when students received £10 for
participation).
3. The maximum number of students who could use
the service if it were run at full capacity.
Scenario 1 was calculated using the TnT data from the
one and four-month visits at the three intervention col-
leges, which were two days each (12 days in total). Sce-
nario 2 was calculated using the incentivised two-day
Fig. 1 TnT flow chart
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TnT seven months follow up at all six colleges (12 days
in total). For Scenario 3, trial design meant using a prag-
matic simulation model to show the maximum number
of students who could be tested in a day with two staff,
three machines and incentives. The reason for doing this
was that the trial design meant we only invited the 85
students already recruited at each college to TnT. If
TnT were rolled out to all colleges in real life, all stu-
dents at the college (range 500–3000 per college) would
be invited for testing. With incentives it is possible that
maximum daily capacity would be achieved. The max-
imum capacity of the service (Scenario 3) was calculated
by creating a simulation model in Python (Python Soft-
ware Foundation. Python Language Reference, Version
2.7) [15]. Details are outlined in Additional file 2; Add-
itional file 5: Supplementary Figure 1, and Additional file
6: Supplementary Figure 2.
Testing and treatment pathway
In order to calculate total costs, a testing and treatment
pathway was mapped containing the different cost con-
tributions and uncertainties. For non-incentivised and
incentivised scenarios, the following pathway parameters
were calculated based on the field data.
 Ratio of male to female participants (because the
samples from males and females took different times
to process)
 Proportion of tests that failed on first run (for
example, because samples did not contain human
DNA) and were repeated
 Proportion of tests that failed because the sample
was inadequate or missing, and therefore the
student was asked to provide another sample
 Proportion of repeat samples provided/not provided
 CT positivity rate
 NG positivity rate
Primary outcomes
Three primary outcomes, based on outcomes used by
the National Chlamydia Screening Programme (NCSP)
[16], were estimated for each uptake scenario:
1. The cost per student screened for CT/NG
2. The cost per CT infection detected
3. The cost per NG infection detected
For each uptake scenario, the cost per student
screened was calculated as: (fixed daily cost + [per
screen cost x number of screens])/number of screens.
The cost per CT or NG infection detected was calcu-
lated as: cost per student screened x number of
screens needed to diagnose one infection (i.e. 100/%
prevalence).
Further analyses
Each college was visited for two consecutive days and
there were typically fewer tests performed on the second
day. Where the CT/NG testing platforms were at full
capacity during college hours or repeat testing was
needed, tests were performed in the evening after stu-
dents had left college, or the following day. For each sce-
nario, the number of test results that were not given on
the same day as the sample was provided is reported, as
well as the number of students who could not be given a
test result because they did not give a valid sample. The
model parameters for estimating maximum capacity
were based on averages per TnT session: 49:51 male; 5%
repeated samples; 20% of failed tests need to be
resampled of whom 25% provide a second sample; 5%
CT positivity rate.
Patient and public involvement
Focus groups were used to inform the study design of
the feasibility trial including incentives. The steering
committee included four student representatives.
Results
CT/NG screening uptake
In total, 291 samples were tested from 254 students: 59
tests when no incentive was given, (at the two interven-
tion visits) and 232 when £10 incentives were given (at
the follow-up visit). Half the students who used the ser-
vice were female (51%, 130/254), and the median age
was 17.9 years.
There was an average of 85 participants recruited per
college. Students from college A provided 26 samples
during the non-incentivised TnT interventions and 37
during the incentivised follow-up. College B and college
C provided 14 and 31 samples, and 19 and 33 samples,
respectively. The three control colleges D, E and F pro-
vided 48, 43 and 43 samples at the incentivised follow
up. Ten samples (3%) required repeat testing. Of these,
four had to be resampled as they were invalid. Invalid
samples (with no human DNA) only occurred during
the incentivised follow-up. Only one student provided a
second valid sample, and so three people could not be
given a result. Overall, 5.8% (17/291) of samples tested
positive for CT and 1.4% (4/291) for NG.
Each of the intervention colleges A-C was visited on
two consecutive days at 1 and 4months. The mean
number of students tested each day per college at the
non-incentivised service was five, the highest uptake in
one day was 17. There were two days when only one
student used the service. By comparison, the average
daily number of students who used the incentivised ser-
vice per college (in all colleges A-F at 7 months follow-
up) was 19 (232 over 12 days) (Table 1).
Kerry-Barnard et al. BMC Health Services Research          (2020) 20:316 Page 4 of 10
Pathway timing
The median time for sampling, testing and receiving the
results of the CT/NG test was 129 min, including the
time needed to repeat test 10 samples. For a negative
result, the median time was 128 min and for a positive
result it was 160min. Each step involved in sampling,
testing and reporting results to students are presented
in Fig. 2, and the associated times are presented in
Additional file 7: Supplementary Table 3. Practical
notes from delivering the TnT service are presented
in Additional file 4 and the steps required to de-
liver TnT as a service and for research are pre-
sented in Additional file 3: Supplementary Table 2.
Estimated costs
The fixed daily cost per college visit was £1056.61. This
comprised of staff costs (£753.60); courier services deliv-
ering three machines (£110.40), diagnostic equipment
hire (£184.20) and consumables (£8.41) (Supplementary
Table 1). Each screen performed cost an additional
£25.45, accounting for the small number of repeat tests
and the additional £2 for the cost of antibiotics to treat
those diagnosed with CT.
Estimating maximum capacity
The model found that the maximum number of students
who could attend the service if it was run at full capacity
using three 4-unit machines was 49 per day. Figure 3 shows
the timeline for each student screened in scenario 3.
Footnotes
The simulation was based on pathway data from 24 days
of providing the TnT service.
In scenario 3, there was insufficient remaining time to
test all the samples that required repeat testing (1% of
total).
‘Handover to HA’ refers to the health advisor being
given the details of students with a positive result so that
they could contact them to provide treatment and ar-
range partner notification.
‘Text result’ is for negative results only.
Screening costs
The cost per student screened and per CT/NG infection
detected for the different uptake scenarios (accounting
for the fixed daily costs and the per screen costs) are
presented in Table 1.
For the non-incentivised service, where CT prevalence
was 5.1% (3/59) and NG prevalence 1.7% (1/59), the
mean cost per student screened was £237 and the cost
per CT/NG infection detected was £4657/£13,970
respectively.
For the incentivised service, where CT prevalence was
6.5% (15/232) and NG prevalence 1.3% (3/232), the cost
per student screened was £91 and the cost per CT/NG
infection detected was £1408/£7042 respectively.
Just as higher uptake of the service reduced the cost
per screen, in settings with higher CT prevalence the
cost per CT infection detected would be lower. For
example, if the prevalence of CT was 8%, the cost per
CT infection detected would be £2960/£1138/£588 for
non-incentivised, incentivised and maximum incenti-
vised uptake (i.e. scenarios 1a, 2 and 3) respectively.
At 10% CT prevalence, the cost per CT infection de-
tected would be £2368/£911/£470 for non-
incentivised, incentivised and maximum incentivised
uptake respectively.
Table 1 Screening costs of providing TnT in technical colleges
Uptake scenario [Students screened per day, per college] Cost per student Cost per CT infection
detected
Cost per NG infection
detected
1a. Average uptake non-incentivised [n = 5] £236.77 £4656.55 £13,969.66
1b. Lowest uptake non-incentivised [n = 1] £1082.06 £21,280.52 £63,841.56
1c. Highest uptake non-incentivised [n = 17] £87.61 £1722.91 £5168.73
1d. Half the average uptake non-incentivised [n = 2.5] £448.10 £8812.54 £26,437.63
1e. Double the average uptake non-incentivised [n = 10] £131.11 £2578.56 £7735.67
2. Average incentivised uptake* [n = 19] £91.06 £1408.44 £7042.22
3. Maximum incentivised uptake* [n = 49] £47.02 £924.64 £2773.92
Footnotes:
Scenario 1a: The average number of students who used the non-incentivised service.
Scenario 1b: The minimum number of students who used the non-incentivised service.
Scenario 1c: The maximum number of students who used the non-incentivised service.
Scenario 1d: Half the average update for the non-incentivised service.
Scenario 1e: Double the average update for the non-incentivised service.
Scenario 2: The average number of students who used the incentivised service.
Scenario 3: The maximum number of students who could use the service if it was run at full capacity using three 4-unit machines.
*Costs for scenarios 2 and 3 include £10 per student incentive
Data for 27 tests (9% of total) run after 5 pm on the first of a two-day TnT visit are included in the calculations
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Fig. 2 Student pathway flowchart showing possible testing scenarios with field data
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Discussion
Principal findings
Using the non-incentivised TnT screening service
piloted in FE colleges, the estimated cost per student
screened for CT/NG, was £237 for the average daily up-
take of the service (5 students/day), or £88 per student
screened at times of highest use of the service. With
highest use (17 students/day) the cost per CT/NG infec-
tion detected was £1723/£5169 respectively. Students
were notified of their results quickly: average time to no-
tification was just over two hours. There was a high
fixed cost (over £1000 per day) for providing the service-
mainly staff costs. This means there is a high cost per
student screened when uptake of the service is low.
However, incentives may be cost effective for case detec-
tion. Our model suggested that if using incentives
achieved maximum capacity (49 students/day), the cost
per student screened and per CT infection detected
would be much lower: £47 and £925 respectively.
Strengths and weaknesses
This is the first UK study to use “real-life” field data as a
basis for cost analysis of providing POC CT/NG services
outside of clinical settings, and the first to evaluate the
use of rapid tests and treatment in the community. The
list of resources used in the TnT study are presented
and could be used as a “how-to” guide for sexual health
services wanting to provide this type of service within
colleges or other community-based settings. Incentivisation
could therefore increase uptake and reduce the per-person
and per-infection screening costs as average attendance was
much higher in the incentivised scenario. TnT may be
reaching students who would not otherwise get tested.
Although at recruitment we advised all participants to get
Fig. 3 Gantt chart showing each student’s pathway in one simulated day of TnT
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tested outside the trial, only 27% of responders reported
doing this.
This type of service could reach groups such as sexu-
ally active adolescents who might otherwise be reluctant
to access community sexual health services or to have
postal CT tests sent to their home. The majority of stu-
dents who were screened as part of TnT did not have a
CT test outside of TnT [6], despite being advised to do
this at recruitment. Most participants (90%) were teen-
agers, and almost half of those tested were male, in
contrast to the NCSP which screens a much higher pro-
portion of females, (despite being an opportunistic
screening programme for any gender) [16]. Males may
be happier to engage with community-based screening
than screening in a clinical setting [17, 18].
The main weakness is that testing uptake may have
been limited by the study design – only students re-
cruited and consented into the study were eligible to use
the service. During our earlier one-day pilot of TnT
when any sexually active student could take part, attend-
ance was considerably higher (34 per day) [19]. Using
the same cost data, the cost per screen in the pilot was
£56.53 and the cost per CT infection detected, £640.66
(as CT prevalence was 11% [3/34]). Secondly, as all stu-
dents were already part of the TnT study, they already
had some knowledge of testing from providing samples
at recruitment and were contacted directly to participate.
This may have increased participation. Selection bias
may have occurred both at recruitment and during test-
ing. However, the prevalence of CT infection in incenti-
vised and non-incentivised TnT was similar (6 and 5%
respectively), suggesting that providing incentives did
not increase levels of testing disproportionally in low-
risk groups - as has been the concern with other screen-
ing strategies [16].
Another limitation is that although most test times
were documented, some were estimates. Real times will
vary according to students’ familiarity with providing
samples and staff skills, as well as locational variables
such as the distance to the nearest bathroom and the
distance between the lab and the meeting space. These
estimates were however based on experience in the field
and, where possible, repeated measurements were taken.
The colleges did not charge for use of rooms, but these
costs might need to be added for screening in other set-
tings. Finally, findings may not be widely applicable. This
study focused on six technical colleges in south London,
an area which has good transport links and where there
is access to multiple NHS sexual health services. Costs,
particularly costs associated with travel and venue hire,
may be higher in other settings. Uptake of services may
also be different in other settings or among older or less
ethnically diverse groups, something which would im-
pact average costs.
The small number of students screened per day and
the high fixed cost of providing the service means that
the per student cost was very sensitive to changes in the
number of students screened per day. Compared to
average update for the non-incentivised service, if twice
as many students were screened, the cost per student
decreased considerably (from £236.77 for 5 screens/day
to £131.11 for 10/day) and if half as many students were
screened it increased considerably (to £448.10 for 2.5
screens/day).
Comparison with other studies
The estimated costs under the average non-incentivised
conditions in this feasibility study (£237 per student
screened) were considerably higher than the London
Integrated Sexual Health Tariff (ISHT) for a CT/NG test
used in numerous clinical settings within the NHS
(National Health Service), which was £45 per attend-
ance in 2017/2018 [20]. They are also higher than the
estimated cost of opportunistic CT screening in the
UK in 2011 – estimated at £61 per CT screening epi-
sode for 2018 (inflated from £51 for NCSP 2011 data)
[16], and in Ireland estimated at £23 per offer (in
2018, inflated and converted from €26 in 2008) [21, 22]. If
demand for the TnT service was very high and the service
was run at full capacity, the cost per student tested would
be £47. This cost is closer to the ISHT and NCSP screen-
ing costs. In addition, if demand were that high, it is likely
the service would be extended over a longer period of time
to meet the demand which would impact costs further.
There have been cost analyses of non-clinic-based
screening in other countries. In “Stamp out Chlamydia”,
an Australian community screening study, the non-
incentivised cost per person screen was £128 (inflated
and converted from 2007 data) [17]. A more recent
study of routine repeat screening in the Netherlands re-
ported screening costs of £100 per-screen (inflated and
converted from 2014 data) [22]. A community CT
screening study in England aimed at men attending
sports clubs estimated that costs ranged from £92 to
£100 per screen (inflated from 2013 estimates) with no
CT infections detected [23].
The high prevalence of CT in the participating FE col-
leges (5.1% non-incentivised and 6.5% when incenti-
vised) resulted in lower costs per infection detected
compared to similar screening studies. The estimated
cost per CT infection diagnosed was £4657 when using
data for non-incentivised average daily uptake of the ser-
vice and £1723 when using data for highest non-
incentivised uptake. This is comparable with both the
“Stamp out Chlamydia” study and the Netherlands based
routine screening study which reported costs of £5395
and £5053 per CT infection detected respectively (in-
flated to 2018 costs) [17, 22]. The TnT model had
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advantages over these testing strategies in that it also
screened for NG and provided same day results and
treatment for CT. Finally, the estimated incentivised
costs in the “Stamp out chlamydia” study were £20 per-
screen and £2378 per CT infection diagnosed compared
to £91 per-screen and £1408 per CT infection detected
for TnT. In both studies when screening was incenti-
vised, the per-screen and per-CT infection diagnosed
costs were less while the rate of CT detection was rela-
tively unchanged.
Conclusion
Although resource intensive, with sufficient uptake and
high rates of STIs, delivering the TnT service in non-
clinical settings may cost a similar amount to CT/NG
testing in clinics. The higher screening cost could be jus-
tified if people using the service were unlikely to use
other less costly services such as postal screening or at-
tending clinics. It could also be appropriate in settings
where community health services are sparse or difficult
to access or where other types of screening for CT/NG
are not available or well accepted.
Higher uptake of the service would considerably re-
duce the cost per screen. Our study suggests incentivis-
ing testing could help increase uptake without reducing
positivity rates. As shown in the process evaluation, in-
centives might also reduce stigma as people can imply
that they are just getting tested for the money. However,
we found this needs to be carefully managed to avoid
abuse (such as impersonation or providing invalid sam-
ples). Finally, our participants’ lack of awareness of STIs
and the need for testing highlight the need for better sex
education for young people and for making regular STI
checks routine.
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Additional file 1: Supplementary Table 1. Costs and consumables
required to deliver the Test n Treat service. The costs incurred
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delivery and the people involved are also listed.
Additional file 4. Practical Notes and Considerations. A description of
some practical details and considerations to be taken into account when
implementating the TnT service in a real-world setting.
Additional file 5: Supplementary Fig. 1. One-day timeline for two
clinical staff providing TnT service – used to estimate maximum capacity
(scenario 3). A timeline of the day for two healthcare staff, one student
facing and one laboratory technician, representing the maximum number
of tasks which they can perform when using three machines.
Additional file 6: Supplementary Fig. 2. One-day timeline for three 4-
unit diagnostic machines – used to estimate maximum capacity (scenario
3). A timeline of the day representing the maximum number of students
(47) that could be tested across 12 modules (3 machines). Students occu-
pied one spot until all machines were saturated.
Additional file 7: Supplementary Table 3. Activities involved in the
delivery of point of care testing and treating of Chlamydia, time taken,
worker occupation and condition under which the process is required. A
description of the processes involved in the point of care delivery is
found in Supplementary Table 3, as well as the time required, the person
actively performing the task and any conditions that might be associated
with the task are also included.
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